1348P The main challenges and potential solutions to improving patient access to oncology combination therapies in Europe

Abstract

Over the past 20 years, there have been significant advances in cancer treatment with the introduction of targeted therapies, which are often used in combination. These treatments are important for many patients due to prolonged survival compared to existing standard of care. However, patient access to combinations has proved difficult, especially when: the constituents are produced by different manufacturers and the constituents are used in multiple indications. Challenges include difficulties in attributing the value of the constituents in the combination and where value and price is not a simple sum of the parts as well as structural limitations of the access process (such as, legal framework and considerations around manufacturers jointly participating in price negotiations).